Karyopharm Therapeutics (KPTI) Revenue (2016 - 2025)
Historic Revenue for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $34.1 million.
- Karyopharm Therapeutics' Revenue rose 1158.08% to $34.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $146.1 million, marking a year-over-year increase of 57.15%. This contributed to the annual value of $146.1 million for FY2025, which is 57.15% up from last year.
- Per Karyopharm Therapeutics' latest filing, its Revenue stood at $34.1 million for Q4 2025, which was up 1158.08% from $44.0 million recorded in Q3 2025.
- Karyopharm Therapeutics' 5-year Revenue high stood at $126.3 million for Q4 2021, and its period low was $22.6 million during Q2 2021.
- In the last 5 years, Karyopharm Therapeutics' Revenue had a median value of $36.9 million in 2022 and averaged $40.2 million.
- In the last 5 years, Karyopharm Therapeutics' Revenue soared by 25974.07% in 2021 and then tumbled by 7340.6% in 2022.
- Over the past 5 years, Karyopharm Therapeutics' Revenue (Quarter) stood at $126.3 million in 2021, then crashed by 73.41% to $33.6 million in 2022, then grew by 0.5% to $33.7 million in 2023, then fell by 9.5% to $30.5 million in 2024, then rose by 11.58% to $34.1 million in 2025.
- Its last three reported values are $34.1 million in Q4 2025, $44.0 million for Q3 2025, and $37.9 million during Q2 2025.